F6020
Fenofibrate
≥99% (TLC), powder, PPARα agonist
Synonyme(s) :
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C20H21ClO4
Numéro CAS:
Poids moléculaire :
360.83
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
256-376-3
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Fenofibrate, ≥99%, powder
Quality Level
assay
≥99%
form
powder
color
off-white
originator
Abbott
storage temp.
room temp
SMILES string
CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2
InChI
1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
InChI key
YMTINGFKWWXKFG-UHFFFAOYSA-N
Gene Information
human ... PPARA(5465)
Application
Fenofibrate has been used:
- to study its effect on plasma lipids, liver phenotype and gene expression
- to study its impact on endothelium-dependent vasodilatation of thoracic aorta
- to administer to NASH knock-in mice along with a high fat diet (HFD) to study its effect
Biochem/physiol Actions
Fenofibrate increases high density lipoprotein levels by reducing cholesteryl ester transfer protein expression. It is used in treating the condition of increased cholesterol levels in the blood, abnormal lipid levels in the body and also hypertriglyceridaemia. Fenofibrate is a lipid regulating drug and proliferator-activated receptor-α (PPARα) mediates its action. It decreases the plasma levels of fibrinogen and C-reactive protein. By this fenofibrate allows better flow-mediated dilatation and reduces the risk of atherosclerosis. Fenofibrate is also known to reduce uric acid levels.
Features and Benefits
This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
pcodes
Hazard Classifications
STOT RE 2 Oral
target_organs
Liver
Classe de stockage
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice
Wouters K, et al.
Febs Letters, 584(5), 1001-1005 (2010)
Fenofibrate
Keating GM and Croom KF
Drugs, 67(1), 121?153-121?153 (2012)
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates
Shiri-Sverdlov R, et al.
Journal of Hepatology, 44(4), 732-741 (2006)